Logo image of FBIO

FORTRESS BIOTECH INC (FBIO) Stock Fundamental Analysis

NASDAQ:FBIO - Nasdaq - US34960Q3074 - Common Stock - Currency: USD

1.62  0 (0%)

After market: 1.6312 +0.01 (+0.69%)

Fundamental Rating

2

Taking everything into account, FBIO scores 2 out of 10 in our fundamental rating. FBIO was compared to 572 industry peers in the Biotechnology industry. FBIO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, FBIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FBIO had negative earnings in the past year.
FBIO had a negative operating cash flow in the past year.
FBIO had negative earnings in each of the past 5 years.
FBIO had a negative operating cash flow in each of the past 5 years.
FBIO Yearly Net Income VS EBIT VS OCF VS FCFFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -45.27%, FBIO perfoms like the industry average, outperforming 49.91% of the companies in the same industry.
Looking at the Return On Equity, with a value of -271.89%, FBIO is doing worse than 73.53% of the companies in the same industry.
Industry RankSector Rank
ROA -45.27%
ROE -271.89%
ROIC N/A
ROA(3y)-28.91%
ROA(5y)-23.67%
ROE(3y)-190.58%
ROE(5y)-154.13%
ROIC(3y)N/A
ROIC(5y)N/A
FBIO Yearly ROA, ROE, ROICFBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K

1.3 Margins

FBIO has a Gross Margin of 60.55%. This is in the better half of the industry: FBIO outperforms 79.75% of its industry peers.
In the last couple of years the Gross Margin of FBIO has declined.
FBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.22%
GM growth 5Y-2.38%
FBIO Yearly Profit, Operating, Gross MarginsFBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K -5K

More info and screens

1

2. Health

2.1 Basic Checks

FBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
FBIO has more shares outstanding than it did 1 year ago.
FBIO has more shares outstanding than it did 5 years ago.
FBIO has a worse debt/assets ratio than last year.
FBIO Yearly Shares OutstandingFBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
FBIO Yearly Total Debt VS Total AssetsFBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

FBIO has an Altman-Z score of -9.88. This is a bad value and indicates that FBIO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of FBIO (-9.88) is worse than 73.18% of its industry peers.
A Debt/Equity ratio of 2.48 is on the high side and indicates that FBIO has dependencies on debt financing.
The Debt to Equity ratio of FBIO (2.48) is worse than 83.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.48
Debt/FCF N/A
Altman-Z -9.88
ROIC/WACCN/A
WACC10.59%
FBIO Yearly LT Debt VS Equity VS FCFFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M -150M

2.3 Liquidity

FBIO has a Current Ratio of 1.23. This is a normal value and indicates that FBIO is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.23, FBIO is not doing good in the industry: 84.90% of the companies in the same industry are doing better.
A Quick Ratio of 1.06 indicates that FBIO should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.06, FBIO is not doing good in the industry: 85.97% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.06
FBIO Yearly Current Assets VS Current LiabilitesFBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.73% over the past year.
The Revenue for FBIO has decreased by -22.81% in the past year. This is quite bad
Measured over the past years, FBIO shows a very strong growth in Revenue. The Revenue has been growing by 25.75% on average per year.
EPS 1Y (TTM)68.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.15%
Revenue 1Y (TTM)-22.81%
Revenue growth 3Y22.83%
Revenue growth 5Y25.75%
Sales Q2Q%-57.9%

3.2 Future

Based on estimates for the next years, FBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 24.98% on average per year.
The Revenue is expected to grow by 56.57% on average over the next years. This is a very strong growth
EPS Next Y63.44%
EPS Next 2Y35.33%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue Next Year-16.96%
Revenue Next 2Y37.78%
Revenue Next 3Y40.93%
Revenue Next 5Y56.57%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FBIO Yearly Revenue VS EstimatesFBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIO Yearly EPS VS EstimatesFBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

FBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBIO Price Earnings VS Forward Price EarningsFBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIO Per share dataFBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as FBIO's earnings are expected to grow with 24.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.33%
EPS Next 3Y24.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FBIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTRESS BIOTECH INC

NASDAQ:FBIO (2/21/2025, 8:17:07 PM)

After market: 1.6312 +0.01 (+0.69%)

1.62

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners17.31%
Inst Owner Change7.38%
Ins Owners20.71%
Ins Owner Change36%
Market Cap44.71M
Analysts82.22
Price Target15.3 (844.44%)
Short Float %17.94%
Short Ratio6.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.78
Dividend Growth(5Y)3.99%
DP-11.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.14%
Min EPS beat(2)-25.23%
Max EPS beat(2)41.5%
EPS beat(4)3
Avg EPS beat(4)23.52%
Min EPS beat(4)-25.23%
Max EPS beat(4)41.63%
EPS beat(8)4
Avg EPS beat(8)16.18%
EPS beat(12)6
Avg EPS beat(12)-12.34%
EPS beat(16)8
Avg EPS beat(16)-17.41%
Revenue beat(2)0
Avg Revenue beat(2)-28.31%
Min Revenue beat(2)-55.48%
Max Revenue beat(2)-1.14%
Revenue beat(4)1
Avg Revenue beat(4)-8.73%
Min Revenue beat(4)-55.48%
Max Revenue beat(4)31.29%
Revenue beat(8)3
Avg Revenue beat(8)6.39%
Revenue beat(12)4
Avg Revenue beat(12)-3.38%
Revenue beat(16)7
Avg Revenue beat(16)-0.86%
PT rev (1m)0%
PT rev (3m)7.14%
EPS NQ rev (1m)7.76%
EPS NQ rev (3m)36.34%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-26.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-27.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.72
P/FCF N/A
P/OCF N/A
P/B 2.11
P/tB 13.49
EV/EBITDA N/A
EPS(TTM)-3.8
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-3.89
FCFYN/A
OCF(TTM)-3.7
OCFYN/A
SpS2.26
BVpS0.77
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.27%
ROE -271.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.55%
FCFM N/A
ROA(3y)-28.91%
ROA(5y)-23.67%
ROE(3y)-190.58%
ROE(5y)-154.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.22%
GM growth 5Y-2.38%
F-Score2
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 2.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 110.74%
Cap/Sales 8.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.06
Altman-Z -9.88
F-Score2
WACC10.59%
ROIC/WACCN/A
Cap/Depr(3y)72.89%
Cap/Depr(5y)91.4%
Cap/Sales(3y)5.6%
Cap/Sales(5y)7.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.15%
EPS Next Y63.44%
EPS Next 2Y35.33%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue 1Y (TTM)-22.81%
Revenue growth 3Y22.83%
Revenue growth 5Y25.75%
Sales Q2Q%-57.9%
Revenue Next Year-16.96%
Revenue Next 2Y37.78%
Revenue Next 3Y40.93%
Revenue Next 5Y56.57%
EBIT growth 1Y40.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.79%
EBIT Next 3Y21.76%
EBIT Next 5Y7.97%
FCF growth 1Y38.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.96%
OCF growth 3YN/A
OCF growth 5YN/A